NEWS
Discover recent news, press, publications & congress and industry news below.
For access to a press kit, please contact a member of the media team at info@anthostherapeutics.com.
Advantages and Disadvantages of Novel Oral Anticoagulants
Jul 6, 2021 | INDUSTRY NEWS
Advantages and Disadvantages of Novel Oral Anticoagulants Looking at the pros and cons of new oral anticoagulants and whether there is a difference between the available agents With the recent introduction of several novel oral anticoagulants (NOACs) on the U.S....
Thromboembolism prophylaxis in orthopaedics: an update
Jul 6, 2021 | INDUSTRY NEWS
Thromboembolism prophylaxis in orthopaedics: an update Dimitrios A. Flevas, Panayiotis D. Megaloikonomos, Leonidas Dimopoulos, Evanthia Mitsiokapa, Panayiotis Koulouvaris, and Andreas F. Mavrogenis Author information Copyright and License information PMC Disclaimer Go...
Safety of new oral anticoagulant drugs: a perspective
Jul 6, 2021 | INDUSTRY NEWS
Safety of new oral anticoagulant drugs: a perspective Juan Antonio Vílchez, Pilar Gallego, and Gregory Y.H. Lip Author information Copyright and License information PMC Disclaimer Go to: Abstract The recent development of new oral anticoagulants (NOACs) offers the...
Blackstone Life Sciences and Novartis Create Anthos Therapeutics to Develop Innovative Targeted Medicines for Cardiovascular Disease
Jul 6, 2021 | INDUSTRY NEWS
Blackstone Life Sciences and Novartis Launch Anthos Therapeutics to Develop Innovative Medicines for Cardiovascular Disease 27 February 2019 Blackstone Life Sciences provides $250M Financing Cambridge, Massachusetts, February 27, 2019 – Blackstone Life Sciences today...
Big Bets on Biotech – Healthy Returns Summit with Nicholas Galakatos
Jul 5, 2021 | INDUSTRY NEWS
Big Bets on Biotech – Healthy Returns Summit with Nicholas Galakatos Over the past decade, Blackstone has invested roughly $16 billion in medicines, therapeutics and health care technologies. Its competitive advantage: A one-stop shop for emerging biotechs looking to...